During the long years a compound is in development no firm’s management will regret taking extra care in researching its acquisition.

Daedalus’ experience, connections, market understanding, and coverage of both academic and commercial orphan assets worldwide ensure our clients an advantage in competing for the most attractive orphan assets.

Licensing: Acquisition, Partnering, and Sale

“Every battle is won or lost before it’s ever fought.” Sun Tzu, The Art of War. The canny fellow must have gotten his start in drug development.

The success or failure of a drug candidate is often determined before the first patient in the first clinical trial is dosed. During the long years a compound is in development no firm’s management will regret taking extra care in researching its acquisition.

A Challenging Environment

Big Pharma is undergoing one of the largest reallocations of corporate capital in American business history, slashing in-house research and spending billions on compounds developed elsewhere. How can a smaller firm hope to compete with a Big Pharma with an external business development staff of hundreds, multiple outside consultants, and tens of billions in their purse?

The greatly increased spending on orphan acquisitions is driving orphan asset inflation, disadvantaging small and medium-sized firms that rely on inlicensing drug candidates to fill their pipelines. To succeed in this environment they require the expert help that Daedalus is well-positioned to provide.

Smaller firms cannot afford to operate conventionally. Bidding directly against Big Pharma is not a winning strategy. Superior information and speed - by identifying the most desirable assets early on Daedalus gives its clients an opportunity to move before they are committed to larger, slower moving competitors that ultimately are in a position to make bids smaller firms cannot match.